Quantity of eligible people: CDEC talked over the uncertainty in the volume of sufferers with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical specialists consulted by CADTH indicated that some patients that are categorized as getting moderate or reasonable disease can have a significant bleeding https://hemgenix40503.blogdal.com/36536788/the-definitive-guide-to-hemgenix